Medpace Holdings, Inc. (MEDP) - Deep Dive Research Report

Prepared 2026-06-02. Healthcare sector / Contract Research Organization (CRO). Listed on Nasdaq.

Concalls used (most recent four): Q1 2026 (Apr 22-23 2026), Q4 2025 (Feb 10 2026), Q3 2025 (Oct 22-23 2025), Q2 2025 (Jul 22 2025).

1. What the Company Does

Medpace runs clinical trials on behalf of the companies that invent new drugs. When a small biotech has a molecule that looks promising in the lab and needs to prove to the FDA (and to regulators in Europe, Asia and elsewhere) that it is safe and that it works in humans, it hires Medpace to design and operate the human trial. Medpace writes the trial protocol, finds the hospitals and doctors (investigator sites) who will enroll patients, ships the drug and the lab kits, collects and cleans the data, runs the blood tests and the medical scans in its own laboratories, and assembles the regulatory dossier. The drug company keeps the molecule and the upside; Medpace gets paid to run the experiment.

This is the contract research organization (CRO) business. The reason it exists is simple: a 25-person biotech with one cancer drug cannot build a global trial machine with regulatory specialists in 46 countries, blood-testing labs, and imaging readers. It would take a decade and hundreds of millions of dollars. Medpace already built that machine and rents it out, trial by trial, to hundreds of sponsors at once.

The founding story matters here. August Troendle started the company in Cincinnati in 1992 as Medical Research Services. Before that he was a medical officer at the FDA, reviewing lipid-lowering (cholesterol) drugs. He came out of the regulator understanding exactly what an approval package needs to contain and where trials go wrong. That regulatory-first instinct became the company's DNA: Medpace markets itself as a "high-science" CRO that runs trials the way an FDA reviewer would want them run, with physician-led therapeutic teams rather than a pure project-management layer. Troendle still runs the company today, still owns roughly 10% directly plus a large indirect stake, and remains the dominant voice on every earnings call.

What makes Medpace genuinely hard to replicate is not any single trial. It is the operating model. Most large CROs grew by acquisition and subcontracting: they bolt together acquired labs, partner with third-party imaging vendors, and staff trials with a flexible contractor workforce. Medpace built almost everything in-house and runs it on one integrated system. Its central lab, bioanalytical lab, imaging core lab, ECG core lab and Phase I unit are all owned and sit on a single laboratory information system feeding a single clinical trial management platform. Every study, in every country, runs on the same instrumentation, the same procedures, and the same data backbone. For a sponsor, that means one accountable vendor instead of stitching together six, and harmonized data that does not need to be reconciled across systems at submission time.

Troendle has repeatedly framed the model as a deliberate refusal to become a labor-supply commodity: Medpace stays full-service, owns its labs, and competes on execution quality and accountability rather than being "just a labor supplier or a commodity staffing platform."

A concrete example. A biotech with a Phase III obesity drug awards Medpace the program. Medpace's metabolic therapeutic team writes the protocol, the regulatory team files it across multiple countries, the clinical operations team activates hundreds of investigator sites, and as patients enroll their blood flows to Medpace's own central lab, their scans to Medpace's imaging core lab, and their ECGs to Medpace's cardiac core lab. All of it lands in one database that the sponsor's tiny team can watch in real time. When the trial reads out, Medpace hands back a clean, regulator-ready package. The sponsor never had to build any of that infrastructure.

2. Business Segments

Medpace is a single-segment business. It reports one operating segment: contract clinical research services delivered through a full-service model. There is no meaningful divisional split in its financial reporting.

That said, the business is best understood along two axes that management discusses constantly, even though they are not formal segments: therapeutic area and the owned laboratory/specialty services that wrap around the core trial-management work. I cover the therapeutic mix in Section 3 (Products) and the lab infrastructure there as well, because that is where the real texture of the business lives. Formal per-segment revenue mix is not disclosed because the company genuinely operates as one integrated unit.

3. Products and Business Detail

Medpace's "product" is the execution of a clinical trial from end to end, but it is delivered through a stack of distinct capabilities, most of which are owned rather than subcontracted. This vertical integration is the heart of the business.

Core clinical operations. The base service is full-service clinical development: protocol design, regulatory submission, site identification and activation, patient recruitment support, clinical monitoring (the people who visit sites and verify the data), medical monitoring, data management, biostatistics, pharmacovigilance (safety reporting), and medical writing for the final submission. Medpace spans Phase I through Phase IV but its center of gravity is mid- to late-stage (Phase II-III) work, where trials are large, global, and where execution quality determines whether a drug gets approved.

Owned laboratory and specialty units. This is what separates Medpace from a pure project-management CRO:

• Central Laboratory - processes the routine blood, urine and tissue samples from every patient in a trial. Because Medpace runs its own, the same instruments and reference ranges apply globally, so data does not have to be normalized across third-party labs.
• Bioanalytical Laboratory - measures drug concentration and biomarkers in patient samples (pharmacokinetics), critical for dose-finding.
• Imaging Core Laboratory - centralized reading of CT/MRI/PET scans, essential in oncology (tumor measurement) and increasingly in metabolic and cardiovascular trials. Medpace has integrated imaging and clinical data onto a single platform via a partnership with Medidata.
• ECG Core Laboratory - centralized cardiac-safety reads, required across most drug classes.
• Phase I Unit - an owned early-phase clinical pharmacology unit at the Cincinnati headquarters where first-in-human dosing is run under direct control.

All four labs share identical instrumentation, follow one set of global operating procedures, and run on a single laboratory information system. This is the "single platform" claim that recurs in management commentary, and it is the operational moat: a sponsor gets one harmonized dataset rather than a reconciliation problem.

Therapeutic areas. Medpace organizes its scientific teams by disease area, and the mix shifts with where biotech funding is flowing:

• Oncology - consistently the largest and, per management, "the strongest segment," roughly 30% of revenue in recent quarters. Cancer trials are complex, imaging-heavy, and play to Medpace's owned-lab strengths.
• Metabolic (obesity, diabetes, NASH/MASH) - the fastest-growing area, riding the GLP-1 wave. Metabolic rose from roughly 25% of revenue in the first half of 2025 to around 30% in Q3 2025, with management noting GLP-1 is about two-thirds of the obesity work. Metabolic trials are large and "fast-burning" (they recruit and consume reimbursable costs quickly), which is why pass-through costs spiked through 2025.
• Cardiology, Central Nervous System (CNS), antiviral/anti-infective, endocrinology, and rare disease round out the book.

Geography. Medpace operates across roughly 46 countries with about 6,300 employees as of March 31, 2026. Headquarters and the owned-lab/Phase I infrastructure sit in Cincinnati's Madisonville neighborhood, where the company committed about $150 million in 2022 to expand the campus and add around 1,500 roles. Recent hiring has concentrated in the United States (to service the metabolic surge), with Asia-Pacific - particularly India - as the secondary growth region; Europe and China saw minimal headcount expansion through 2025.

Backlog and the pre-backlog pool. Two operational metrics drive the whole business. Backlog is contracted future work (about $2.9 billion as of March 31, 2026). The pre-backlog pool is awarded work that has not yet converted into formal backlog because patient enrollment has not started; management flagged in Q3 2025 that this pool was up 30% year-over-year and had grown larger than backlog itself. The net book-to-bill ratio (net new awards divided by revenue) is the single most-watched leading indicator: above 1.0 means the order book is growing faster than it is being consumed.

4. Customers

Medpace's customer base is unusually skewed toward small and mid-sized biotech. Roughly 90% of its clients are small-to-mid biopharma companies, and they generate the overwhelming majority of revenue (about 96% in 2024; small biopharma alone was 81% of 2025 year-to-date revenue, up from 79% a year earlier). This is a deliberate strategic choice, not an accident of who walks in the door.

Who buys and why. The buyer is typically a small biotech's head of clinical development or its CEO/CMO - a tiny team, often venture- or public-market-funded, with one or a few assets and no internal trial infrastructure. They are choosing among CROs at the moment they need to run a pivotal trial. Their decision criteria are speed, scientific credibility, and single-vendor accountability. A large pharma company can manage a dozen specialty vendors; a 30-person biotech cannot, and it cannot afford a trial that slips because of a data-reconciliation problem between a third-party lab and the CRO. Medpace's pitch to this buyer is: one vendor, owned labs, harmonized data, physician-led therapeutic teams, and senior attention. That is precisely the package a capital-constrained biotech values most.

Switching costs. Within a given program, switching costs are high and increase over time. Once a trial is underway across hundreds of sites with Medpace's labs processing every sample, moving to another CRO mid-study means re-papering site contracts, re-validating lab data, and risking the regulatory integrity of the dataset. The lock-in is per-program rather than per-relationship: a sponsor can choose a different CRO for its next molecule, but rarely mid-trial. The flip side is that Medpace must re-win each new program on its merits.

Concentration. Concentration is low and is a feature, not a bug. The top ten customers were about 29% of 2024 revenue, the top five about 22%, and no single customer exceeded 10%. Because Medpace serves a long tail of biotechs rather than a handful of big-pharma giants, the loss of any one client is survivable. The risk is not customer concentration but funding concentration: when biotech capital markets freeze, a whole cohort of small sponsors cuts or cancels trials at once.

Contract structure. Contracts are typically long-term, structured as fixed-price or unit-based, and tied to milestones and patient activity. Revenue is recognized as work is performed against backlog. This gives reasonable visibility (the backlog plus pre-backlog pool), but it also means a sponsor can cancel a contract if its drug fails or its funding dries up - and cancellations flow straight out of backlog, which is exactly the dynamic that has dominated recent calls.

5. Competitive Landscape

The CRO industry is a tiered oligopoly at the top with a long tail of regional and niche players. Medpace sits in a distinctive position: it is one of the larger pure-play clinical CROs, but it competes by being narrower and more vertically integrated than the giants rather than bigger.

The named competitors:

• IQVIA - the largest, combining a massive CRO with a healthcare-data and analytics business. Competes across every therapeutic area and trial phase, with scale and data assets Medpace cannot match.
• ICON plc - grew large through the PRA Health Sciences merger; a full-service global CRO and Medpace's closest pure-play peer in scale.
• Thermo Fisher / PPD - PPD is now inside Thermo Fisher, pairing a large CRO with lab-supply and pharma-services scale.
• Labcorp / Fortrea - Labcorp spun out its CRO business as Fortrea; both compete in clinical development and central-lab services.
• Parexel - large private full-service CRO, strong in late-stage and regulatory consulting.
• Syneos Health - full-service CRO with an integrated commercial arm (now private).
• WuXi AppTec / WuXi Clinical - more weighted to preclinical and lab services, but a competitor at the discovery/early end and a geopolitical wildcard given US scrutiny of Chinese biopharma-services firms.

Where Medpace wins. Against the giants, Medpace wins with biotechs that want one integrated, accountable vendor rather than a sprawling matrix. Its owned labs and single data platform let it move fast and hand back clean data, and its physician-led therapeutic teams give it credibility in complex areas like oncology and metabolic disease. It also wins on cost discipline and execution speed - it has a reputation for running tight, on-budget trials, which matters enormously to a sponsor burning venture cash. Management consistently reports stable win rates even as the number of CROs bidding per opportunity has risen (sometimes six or more versus historical norms).

Where Medpace is exposed. It deliberately does not chase the largest pharma master-service-agreement relationships, where the mega-CROs dominate with global scale and preferred-provider status. It is far more exposed to the biotech funding cycle than IQVIA, whose data business smooths the swings. And it is smaller, so a few large cancellations move its numbers visibly, as 2025-2026 showed.

Barriers to entry. High at Medpace's level, low at the bottom. Anyone can start a small regional CRO. But replicating Medpace's owned global lab network, single integrated data platform, multi-country regulatory teams, and three decades of therapeutic process knowledge would take a decade and enormous capital, and even then the new entrant would lack the track record sponsors trust at submission time. The real barrier is not technology; it is the integrated operating system plus reputation built trial by trial.

6. Industry

What drives demand. The CRO industry's demand comes from biopharma R&D spending and the long-run trend of outsourcing trial execution rather than building it in-house. Two engines matter most for Medpace specifically. First, biotech funding - the flow of venture capital and public-market (IPO/follow-on) money into small drug developers. When funding is plentiful, biotechs start trials; when it freezes, they cancel them. This is the single biggest swing factor in Medpace's order book. Second, therapeutic waves - right now the GLP-1/obesity and broader metabolic boom is pulling enormous trial volume, which is why Medpace's metabolic mix and pass-through costs surged through 2025.

Size and growth. The pharmaceutical CRO market is estimated at roughly $43-45 billion in 2025, with projections to $80-88 billion by the early-to-mid 2030s, implying a high-single-digit CAGR (around 7-8%). The clinical segment is the bulk of it (about 75% of the market), and oncology is the single largest therapeutic slice (roughly 31% of CRO spend). These figures come from third-party market researchers (Grand View, Fundamental Business Insights) and should be read as directional rather than precise.

Where Medpace sits in the chain. Medpace is the execution layer between the drug innovator (biotech/pharma) and the regulator (FDA/EMA/others). It does not discover drugs and it does not manufacture or sell them; it runs the human experiment that converts a molecule into an approvable dataset. Its owned labs mean it also occupies part of the specialty-services layer (central lab, imaging, bioanalytical) that other CROs subcontract.

Regulation. The industry is shaped entirely by regulatory requirements - trials exist because regulators demand evidence. Good Clinical Practice standards, FDA/EMA guidance, and country-by-country approval regimes define the work. This is a tailwind: rising regulatory complexity raises the value of a CRO that knows how to navigate it. A specific watch item is US scrutiny of Chinese biopharma-services firms (the BIOSECURE-type policy thread), which is a relative tailwind for US-based Medpace versus WuXi.

Cyclicality. The industry is moderately cyclical, but the cycle is driven by biotech capital markets and interest rates rather than the broad economy. Higher rates and risk-off sentiment dry up biotech funding, which shows up as cancellations and weaker bookings 6-12 months later. Medpace, with its biotech-heavy book, feels this cycle more sharply than the diversified giants.

Tailwinds: secular outsourcing of trials, GLP-1/metabolic boom, oncology pipeline depth, rising regulatory complexity, US reshoring of biopharma services. Headwinds: biotech funding volatility, customer M&A removing sponsors, and the long-term question of whether AI compresses the labor content of trial execution (discussed in Section 8).

7. Growth Triggers

All items below are drawn directly from the four most recent earnings calls and cited to the call.

• Pre-backlog pool up 30% year-over-year, larger than backlog itself - the awarded-but-not-yet-converted work that should feed future revenue (Q3 2025 concall, Oct 22-23 2025).

  "The overall pipeline of awarded studies ... is larger than our backlog itself and is up 30% over the year."

• Metabolic / GLP-1 trial expansion - metabolic rose from ~25% of revenue in H1 2025 to ~30% in Q3 2025, driving US hiring and reimbursable activity (Q3 2025 concall, Oct 22-23 2025; repeated Q2 2025, Jul 22 2025). Note: management expects this to normalize down as a share of revenue through 2026, so it is a near-term driver rather than a perpetual one.

• Expected bookings recovery - management said it expected awards to rise after a soft Q1 2025 (Q2 2025 concall, Jul 22 2025).

  "We do expect bookings to increase now."

• Headcount acceleration to service awarded work - hiring stepped up into 2026 to deliver the awarded book, concentrated in the US and India (Q3 2025 concall, Oct 22-23 2025). Management guided mid-to-high single-digit headcount growth for 2026, deliberately below revenue growth, to capture productivity from improved retention (Q4 2025 concall, Feb 10 2026).

• Oncology as the stable growth foundation - described as "the strongest segment," providing a steady revenue base independent of the metabolic swing (Q4 2025 concall, Feb 10 2026).

• AI deployment in operations and feasibility/site-selection analytics - tooling rolled out in two buckets (efficiency and data analytics), though management explicitly cautioned not to expect a 2026 productivity benefit because investment costs offset it (Q4 2025 concall, Feb 10 2026).

• Continued capacity and campus expansion - the Cincinnati headquarters expansion underpins the hiring runway (referenced across calls; original $150M commitment in 2022).

8. Key Risks

Cancellations and a sub-1.0 book-to-bill. This is the live, acute risk. Backlog cancellations hit their highest level in over a year in both Q4 2025 and Q1 2026, and the Q1 2026 net book-to-bill fell to 0.88 - meaning the order book shrank faster than it was consumed. Management was unusually candid that without relief, growth is at risk.

Troendle, Q1 2026: the company needs "either cancellations to abate or gross awards to improve," and there is "area for concern" about revenue beyond the next 12 months of backlog coverage.

The mechanism: cancelled contracts leave backlog instantly, while weak gross bookings fail to refill it, so revenue 2-4 quarters out softens. This is a high-probability moderate-to-serious drag right now, not a tail risk.

Biotech funding dependence. Because ~90% of clients are small/mid biotech and ~96% of revenue comes from them, Medpace's order book is a leveraged bet on biotech capital markets. A funding freeze (driven by rates, risk-off sentiment, or a sector drawdown) translates into cancellations and thin bookings across a whole cohort at once. Management ties cancellation swings directly to "biotech sponsor funding constraints" (Q2 2025). High-probability cyclical risk that recurs every cycle.

Customer M&A. When a biotech client is acquired, the acquirer usually moves the work in-house or to its own preferred CRO, and Medpace loses the program. Management was blunt about it.

Troendle, Q1 2026: "acquisitions are not good for us," with Medpace typically "cut out of future work" post-acquisition.

In an active biotech M&A environment, this is a steady, hard-to-control leakage from backlog.

Metabolic concentration and normalization. The GLP-1 boom inflated both revenue and pass-through costs and pulled the mix toward metabolic. Management expects metabolic to normalize down as a share of revenue in 2026. If metabolic trials wind down faster than oncology and other areas refill the book, growth and mix both weaken. Moderate probability, already partly guided.

AI as a structural headwind to a labor model. Most companies frame AI as upside. Troendle did the opposite, which is notable.

Q4 2025: AI is "a net negative to ... a service company" that depends on staff productivity, since automation could reduce the volume of billable engagement over time.

The mechanism: Medpace bills for human-delivered work; if AI lets sponsors run trials with less CRO labor, the addressable spend per trial could compress. Low-probability near-term, but a genuine long-term structural question management itself raised.

Key-man and leadership-transition risk. August Troendle is founder, CEO, dominant shareholder, and the intellectual center of the "high-science" model. President Jesse Geiger departed after 18.5 years, and Troendle reassumed presidential duties on an interim basis (Q1 2026). The bench is described as deep, but the concentration of strategic authority in one founder-CEO is a real succession risk for a company this dependent on its operating philosophy.

Pass-through cost volatility. Reimbursable (pass-through) costs ran high through 2025 (peaking around 44% of revenue in Q1 2026) because of the metabolic mix. These are low-margin dollars that inflate reported revenue and distort growth optics; as they roll off, headline growth decelerates even if the underlying service business is healthy. A modeling/optics risk more than an economic one, but it complicates the read on the business.

9. Walk the Talk

The four calls in sequence are Q2 2025 (Jul 22 2025), Q3 2025 (Oct 22-23 2025), Q4 2025 (Feb 10 2026), and Q1 2026 (Apr 22-23 2026). The arc shows a management team that is consistently candid and historically conservative, but that has been overtaken by a deteriorating bookings environment in the most recent two quarters - and, to its credit, has said so plainly rather than spinning it.

In Q2 2025, after a weak first quarter, management leaned forward. Troendle said:

"We do expect bookings to increase now."

and the team raised full-year 2025 revenue guidance by $280 million at the midpoint, citing the metabolic acceleration and an improving funding environment. They also set an explicit near-term target: book-to-bill returning above 1.15 in Q3, while cautioning it was "still not anywhere near a slam dunk." This was a specific, datable, falsifiable commitment.

In Q3 2025, they delivered and then some. Net awards jumped 47.9% year-over-year to a 1.20 book-to-bill, beating their own 1.15 target. The pre-backlog pool was up 30% and larger than backlog. Guidance was raised again. On this commitment, management did exactly what it said it would, and the candor about it being "not a slam dunk" the prior quarter makes the delivery more credible, not less. They then set the next target: 1.15 book-to-bill for Q4.

In Q4 2025, the Q4 target was missed. Book-to-bill came in at 1.04, below the 1.15 they had guided, and cancellations hit "the highest level ... in over a year" on a broad basis, with some studies ending early because the underlying compounds underperformed. Management did not hide it.

Troendle: "Cancellations were elevated again in Q4."

They set conservative 2026 guidance (low-double-digit revenue growth, decelerating from 2025's ~20%) and were explicit that the environment was only "adequate and headed in the right direction." This is the behavior of a team that calibrates rather than cheerleads - they missed their own bookings target and labeled cancellations an "open concern" in the same breath.

In Q1 2026, the trend worsened. Book-to-bill fell to 0.88, cancellations again hit their highest in over a year (concentrated in oncology and cardiovascular), and gross bookings were weak. Critically, management maintained full-year 2026 guidance rather than cutting it, but paired that with an unusually direct warning that there is "area for concern" beyond the next 12 months of backlog coverage and that the company needs "either cancellations to abate or gross awards to improve." Holding guidance while flagging the downside risk is a defensible stance, but it is the first call in the sequence where the stated outlook and the leading indicators visibly diverge - something to watch closely at Q2 2026.

The verdict: this is management that does what it says and tells the truth about what it cannot control. They beat the Q3 target, missed the Q4 target, and disclosed both without spin; they have a multi-year reputation for conservative guidance and on-budget execution. The one yellow flag is that Q1 2026 guidance now rests on a bookings recovery that the most recent two quarters have not yet shown. Their credibility is high; the question is whether the cycle, not their honesty, lets them deliver.

10. Shareholder Friendliness Index

Dividends. Medpace pays no dividend and never has since its 2016 IPO. Dividend per share for each of the last three years (2023, 2024, 2025) was zero. This is consistent with a founder-led growth company that returns capital entirely through buybacks; there is nothing unusual to explain beyond the deliberate choice not to initiate one.

Buybacks and dilution. Medpace returns capital aggressively through repurchases. It bought back roughly 781,000 shares for about $144 million in 2023, stepped up through 2024 (including about 527,000 shares for ~$174 million in Q4 2024 alone), and then dramatically accelerated in 2025, repurchasing about 2.96 million shares for roughly $913 million. The board expanded the authorization in February 2025 (an additional $600 million) and again during 2025, leaving about $822 million remaining at year-end. Notably, the 2026 guidance assumes no further buybacks, even though the authorization is intact - management repurchases opportunistically rather than on a schedule, and signaled it would keep doing so "as we always have" when valuation is attractive. Shares outstanding fell from about 30.75 million (end-2023) to about 30.63 million (end-2024) to a roughly 29.2 million diluted base assumed for 2026 - a genuine net reduction, with the steepest cut coming from the 2025 buyback that retired close to 10% of the float. Dilution from stock compensation is more than offset by repurchases; the share count is shrinking.

Verdict: Returns Capital - no dividend, but a large and opportunistically timed buyback program that has meaningfully reduced the share count, funded entirely from strong operating cash flow.

11. Insider Activities

The listing venue is Nasdaq, so the primary source is SEC Form 4 filings via EDGAR (corroborated through StockTitan/Benzinga reporting of those filings). All material insider activity in the last 12 months is concentrated in one person: founder-CEO August Troendle. No open-market insider purchases were located.

Recent transactions (most recent first):

Buys - read the signal. There were no open-market purchases by any insider in the trailing 12 months. The strongest bullish signal available in this section - an insider stepping in to buy with their own cash - is simply absent. That is not itself bearish (founders of mega-cap-stake companies rarely add to an already-enormous position), but it means there is no conviction-buy signal to report.

Sells - work out the why. Every material transaction is a Troendle sale, executed via limit orders during open trading windows. The most likely explanation is straightforward founder diversification: Troendle built and still controls the company, and after a multi-year run he has been trimming a vastly concentrated position. The filings describe limit orders placed during open windows rather than formal Rule 10b5-1 plans, and no footnote discloses a specific reason (estate, charity, or tax), so the precise rationale is "reason not disclosed," with diversification the reasonable inference. The crucial context: even after selling well over 200,000 shares across late 2025, Troendle still directly owns about 833,627 shares and indirectly owns about 4,733,019 shares through Medpace Investors, LLC - roughly 5.57 million shares in total. He has sold a small fraction of his stake and remains by far the largest holder, fully aligned with shareholders.

Net assessment. Insiders are net sellers, but the activity is entirely one person (the founder-CEO) trimming a still-dominant position through routine open-window limit-order sales, with no other officers or directors selling in size and no offsetting buys. There is no cluster, no acceleration tied to the deteriorating bookings outlook that would suggest information-driven dumping, and the retained stake is enormous. Read: neutral. This is founder diversification, not a red flag - but note the absence of any insider buying at a time when the stock has fallen and bookings have softened, which would have been a reassuring counter-signal had it appeared.

12. Scenarios

Bull case. Biotech funding thaws over the next year as rates ease and the IPO/follow-on window reopens. The cohort of small sponsors that paused or cancelled trials comes back, cancellations abate, and gross bookings rebuild - book-to-bill climbs back above 1.0 and then toward the 1.15-1.20 range Medpace hit in 2025. The huge pre-backlog pool that management flagged converts into backlog as enrollment starts, and oncology provides a stable base while a fresh wave of metabolic, cardiovascular, and rare-disease programs refills the book. Medpace's owned-lab, single-platform model keeps winning the integrated full-service work that capital-efficient biotechs need, win rates hold even against crowded bidding, and the deliberately restrained headcount plan converts improved retention into productivity and margin. The aggressive buyback keeps shrinking the share count into the recovery. Troendle's interim presidency hands off cleanly to a deep bench, and the company resumes the steady, on-budget compounding that built its reputation.

Base case. The bookings environment stays "adequate" rather than strong, roughly as management framed it. Cancellations remain elevated but not catastrophic, gross awards grind sideways, and book-to-bill hovers around or just below break-even for a few quarters before slowly recovering. Revenue growth decelerates from the ~20% of 2025 to the low-double-digit pace management guided for 2026, helped by backlog conversion and the metabolic work still burning off, even as the pass-through cost tailwind fades and optically slows headline growth. Oncology anchors the book, metabolic normalizes down as a share of revenue, and Medpace continues to win its share of full-service biotech mandates without dramatic gains or losses. Buybacks continue opportunistically, the share count keeps drifting lower, and the leadership transition proceeds without disruption. Nothing breaks; nothing dazzles.

Bear case. Biotech funding stays tight or worsens, and the cancellation wave that began in late 2025 deepens. Book-to-bill stays below 1.0 for several consecutive quarters, the pre-backlog pool fails to convert because sponsors keep delaying or killing programs, and backlog coverage beyond 12 months thins out - exactly the "area for concern" Troendle named in Q1 2026. A surge of biotech M&A removes a steady stream of sponsors, with Medpace "cut out of future work" each time an acquirer absorbs a client. The metabolic boom rolls off faster than oncology and other areas can refill, so both growth and mix weaken at once, and the pass-through roll-off makes the deceleration look even sharper. Over a longer horizon, AI begins to compress the labor content of trial execution that Medpace bills for - the structural risk management itself raised - pressuring the per-trial revenue pool. The founder-CEO's interim presidency drags on without a clear successor, and the market starts to question whether the high-science, high-touch model can grow through a prolonged funding winter. Guidance, held firm through Q1 2026, finally has to come down.

Sources

Concall transcripts (the four most recent):

• Medpace Q1 2026 Earnings Transcript - The Motley Fool (Apr 23 2026)
• Medpace Q4 2025 Earnings Call Transcript - The Motley Fool (Feb 10 2026)
• Medpace Q3 2025 Earnings Call Transcript - The Motley Fool (Oct 2025)
• Medpace Q2 2025 Earnings Call Transcript - Investing.com (Jul 22 2025)

Company filings & primary results:

• Medpace Q1 2026 Form 8-K results - SEC EDGAR
• Medpace Q4 2025 Form 8-K results - SEC EDGAR
• Medpace Q3 2025 Form 8-K results - SEC EDGAR
• Medpace Investor Relations
• Medpace full-service CRO model

Insider transactions (Form 4):

• Troendle Form 4 - Nov 20-21 2025 sale - StockTitan
• Troendle $61.97M sale - Benzinga
• Troendle Dec 2025 sale - Benzinga

Industry, competitors, buybacks, business model:

• Medpace - Wikipedia
• Pharmaceutical CRO Market Report 2025-2030 - GlobeNewswire
• Pharmaceutical CRO Market Size - Grand View Research
• Medpace adds $1B buyback - InsideArbitrage

Section 13 (Further Reading) is omitted: SemiAnalysis, Stratechery, and MBI Deep Dives have no qualifying coverage of Medpace.

A note on two charts where I used judgment: the therapeutic-area pie is anchored on the disclosed oncology (~30%) and metabolic (~30%) figures from the Q3 2025 call, with the remaining areas estimated to sum to 100% (Medpace does not disclose a full therapeutic breakdown); and the 2024 buyback figure (~$250M) is an approximation built up from the disclosed Q4 2024 (~$174M) plus earlier-quarter activity. Treat both as directional.